Normal Hepatic Function, Severe Hepatic Impairment
Conditions
Brief summary
The objective of this study is to evaluate the pharmacokinetics, safety, and tolerability of one dose of vorasidenib in participants with severe impaired hepatic function compared to participants with normal hepatic function. The study includes a screening phase, a treatment period, and a follow-up period. During the first part of the treatment period, from Day 1 through Day 4, participants will remain in-house in the clinical research unit. In the second part of the treatment period, from Day 5 through Day 43, participants can go home but may also choose to remain in-house. The entire study, including screening and follow-up, will last up to 77 days. Participants may undergo blood tests, heart tests (electrocardiogram (ECG)), vital sign checks, and physical exams.
Interventions
DRUGVorasidenib 20mg
Vorasidenib 20mg will be taken by mouth on Day 1
Sponsors
Institut de Recherches Internationales Servier (I.R.I.S.)
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
Participants with hepatic impairment: * Diagnosis of cirrhosis due to parenchymal liver disease * Considered to have a Child-Pugh score of 10 to 15, consistent with severe HI, and a documented medical history of liver disease. Participants must be clinically stable (no acute episodes of illness due to deterioration in hepatic function) for at least 1 month prior to screening and are likely to remain stable throughout the study. * Grade 0 or Grade 1 hepatic encephalopathy considered stable per Investigator assessment without exacerbation within the 6 months prior to screening. * Currently on a stable medication regimen, defined as not starting new drug(s) or significantly changing drug dosage(s) within 14 days preceding Day 1. * Non-hepatic abnormal laboratory values must be not clinically significant as judged by the Investigator (or designee) and the study medical monitor. * Anemia secondary to hepatic disease is acceptable if hemoglobin is ≥ 9 g/dL and anemia symptoms are not clinically significant. Platelet count must be ≥ 35,000 platelets. * QT interval corrected for heart rate using Fridericia's formula (QTcF) of ≤ 480 msec. Matched-control participants: * Healthy, with normal hepatic function with a Child-Pugh score below 5. * Resting blood pressure of 90 to 140 mmHg (systolic) and 40 to 90 mmHg (diastolic). * QTcF of ≤ 450 msec. * Participant must match hepatically impaired participants with respect to sex, race, age (±10 years), smoking status (smoke or vape ≤ 10 cigarettes/day), and body mass index (±20%).
Exclusion criteria
for all participants: * Women of childbearing potential (WOCBP) who are pregnant, lactating, or planning to become pregnant within 90 days after the dose of vorasidenib. * The participant is using hormonal contraceptives * Use of any other investigational drug or device within 30 days (or 5 half-lives if known, whichever is longer) before the dose of vorasidenib * Consumption of any nutrients known to modulate CYP450 enzymes activity (e.g., grapefruit or grapefruit juice, pomelo juice, star fruit, Seville \[blood\] orange products) within 14 days before vorasidenib administration. * Consumption of alcohol-containing foods or beverages or caffeine- or xanthine-containing foods or beverages (including, but not limited to, teas \[including decaffeinated teas\], coffees \[including decaffeinated coffees\], colas \[including decaffeinated colas\], energy drinks, gum containing caffeine, and chocolate (including foods and beverages containing chocolate) within 48 hours prior to admission * Any history (within 5 years prior to screening) or presence of malignancy, except for adequately treated basal cell and squamous cell carcinoma of the skin * History within the previous 12 months of alcohol consumption exceeding 2 standard drinks per day on average (1 standard drink = 12 oz beer, 5 oz wine, or 1.5 oz spirits) * In the opinion of the Investigator, the participant is not suitable for entry into the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Maximum observed plasma concentration (Cmax) | Through the end of the treatment period (approximately 43 days) |
| Area under the plasma concentration-time curve (AUC) from time 0 to the last quantifiable concentration (AUC0-t) | Through the end of the treatment period (approximately 43 days) |
| AUC from time 0 extrapolated to infinity (AUC0-inf) | Through the end of the treatment period (approximately 43 days) |
| Time to reach Cmax (Tmax) | Through the end of the treatment period (approximately 43 days) |
| Apparent terminal elimination half-life (t1/2) | Through the end of the treatment period (approximately 43 days) |
| Apparent oral clearance (CL/F) | Through the end of the treatment period (approximately 43 days) |
| Apparent volume of distribution (Vz/F) | Through the end of the treatment period (approximately 43 days) |
| Apparent terminal elimination rate constant (Kel) | Through the end of the treatment period (approximately 43 days) |
Secondary
| Measure | Time frame |
|---|---|
| Number of Adverse Events (AEs) and Serious Adverse Events (SAEs) | Through the end of the study (approximately 50 days) |
| Number of participants experiencing clinically significant changes in laboratory assessments, vital signs, ECG results, or physical examination findings | Through the end of the study (approximately 50 days) |
Countries
United States
Contacts
CONTACTInstitut de Recherches Internationales Servier (I.R.I.S.), Clinical Studies Department
Outcome results
None listed